ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.72
0.20%
US Tech 100
20,897.20
-1.35%
S&P 500
5,970.84
-1.11%
US Dollar vs CAD
1.44185
0.00%
Bitcoin
94,293.09
0.14%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Halozyme Therapeutics Incorporated (HALO)

  7. Halozyme Therapeutics Incorporated (HALO) News

HALO

Halozyme Therapeutics (HALO)

Halozyme Therapeutics Incorporated
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:HALO
DateTimeSourceHeadlineSymbolCompany
12/03/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
12/03/20243:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
11/27/20247:30AMPR Newswire (US)Halozyme to Present at Upcoming Investor ConferencesNASDAQ:HALOHalozyme Therapeutics Incorporated
11/22/20247:35AMPR Newswire (US)Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in DiscussionsNASDAQ:HALOHalozyme Therapeutics Incorporated
11/14/20243:15PMPR Newswire (US)Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash TransactionNASDAQ:HALOHalozyme Therapeutics Incorporated
11/12/20248:36AMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:HALOHalozyme Therapeutics Incorporated
10/31/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HALOHalozyme Therapeutics Incorporated
10/31/20243:01PMPR Newswire (US)HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
10/24/20245:30AMPR Newswire (US)HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPENASDAQ:HALOHalozyme Therapeutics Incorporated
10/23/20243:30PMPR Newswire (US)Halozyme to Report Third Quarter 2024 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
10/16/20245:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
10/16/20243:14PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
10/15/20243:34PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
10/10/20247:09AMInvestorsHub NewsWireZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor UseNASDAQ:HALOHalozyme Therapeutics Incorporated
10/09/20244:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
10/09/20243:09PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
10/08/20243:08PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
10/03/20247:00AMPR Newswire (US)Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®NASDAQ:HALOHalozyme Therapeutics Incorporated
09/26/20245:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
09/26/20243:05PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
09/25/20243:00PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
09/24/20243:05PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
09/18/20245:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
09/18/20243:01PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
09/17/20243:03PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
09/13/202412:30PMPR Newswire (US)Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple SclerosisNASDAQ:HALOHalozyme Therapeutics Incorporated
09/12/20247:00PMPR Newswire (US)Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of CancerNASDAQ:HALOHalozyme Therapeutics Incorporated
09/12/20244:56PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
09/12/20243:12PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
09/11/20243:05PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
 Showing the most relevant articles for your search:NASDAQ:HALO

Your Recent History

BIT
UC6126
Unicredit Bank
BOV
BPAC5R
BTG PACTUAL PNA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads